Arvinas, Pfizer find new partner for ‘Protac’ breast cancer drug
BioPharma Dive
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.
pharminent
May 12, 2026 (Last updated: May 16, 2026)
BioPharma Dive
A deal with Rigel Pharmaceuticals ends months of uncertainty about the future of Veppanu, a first-of-its-kind, newly approved medicine with a murky financial outlook.